RBE-weighted dose in carbon ion therapy for ACC patients: Impact of the RBE model translation on treatment outcomes. (December 2019)
- Record Type:
- Journal Article
- Title:
- RBE-weighted dose in carbon ion therapy for ACC patients: Impact of the RBE model translation on treatment outcomes. (December 2019)
- Main Title:
- RBE-weighted dose in carbon ion therapy for ACC patients: Impact of the RBE model translation on treatment outcomes
- Authors:
- Molinelli, Silvia
Bonora, Maria
Magro, Giuseppe
Casale, Silvia
Dale, Jon Espen
Fossati, Piero
Hasegawa, Azusa
Mirandola, Alfredo
Ronchi, Sara
Russo, Stefania
Preda, Lorenzo
Valvo, Francesca
Orecchia, Roberto
Ciocca, Mario
Vischioni, Barbara - Abstract:
- Highlights: mMKM to LEM conversion of dose prescription/constraints affects treatment outcomes. LEM-68.8 Gy(RBE) correctly reproduces mMKM-64 Gy(RBE) for ACC patients. ACC relapses were mainly related to CTV under-dosage due to OARs sparing. mMKM OARs constraints require correction when applied to LEM plans. Abstract: Purpose/objective: The purpose of this study is to assess the impact of the conversion scheme for relative biological effectiveness (RBE)-weighted dose (DRBE ), implemented at our center, on treatment outcomes of adenoid cystic carcinoma (ACC) patients. Material/methods: Treatment plans of 78 ACC patients, optimized with the Local Effect Model (LEM), were recalculated with the modified Microdosimetric Kinetic Model (mMKM). DRBE to 95%, 50% and 2% (DV% ) of the clinical target volume (CTV), were selected as relevant parameters to compare LEM and mMKM DRBE . The pattern of failure of ACC treatments was analyzed in relation to uncertainties involved in the DRBE translation methodology. Results: mMKM recalculations of LEM plans, optimized to a prescription dose of 68.8 Gy(RBE), showed a D50% 8% higher, on average, than the expected value (60.8 Gy(RBE)), closer to the most frequently used mMKM prescription DRBE (64 Gy(RBE)). D95% and D2% deviations, with respect to the optimization goals in the two RBE systems, increased of 0.5% and 14.2%, respectively, due to the steeper mMKM RBE variation along the beam path. Local recurrences were mainly (63%) reported in areasHighlights: mMKM to LEM conversion of dose prescription/constraints affects treatment outcomes. LEM-68.8 Gy(RBE) correctly reproduces mMKM-64 Gy(RBE) for ACC patients. ACC relapses were mainly related to CTV under-dosage due to OARs sparing. mMKM OARs constraints require correction when applied to LEM plans. Abstract: Purpose/objective: The purpose of this study is to assess the impact of the conversion scheme for relative biological effectiveness (RBE)-weighted dose (DRBE ), implemented at our center, on treatment outcomes of adenoid cystic carcinoma (ACC) patients. Material/methods: Treatment plans of 78 ACC patients, optimized with the Local Effect Model (LEM), were recalculated with the modified Microdosimetric Kinetic Model (mMKM). DRBE to 95%, 50% and 2% (DV% ) of the clinical target volume (CTV), were selected as relevant parameters to compare LEM and mMKM DRBE . The pattern of failure of ACC treatments was analyzed in relation to uncertainties involved in the DRBE translation methodology. Results: mMKM recalculations of LEM plans, optimized to a prescription dose of 68.8 Gy(RBE), showed a D50% 8% higher, on average, than the expected value (60.8 Gy(RBE)), closer to the most frequently used mMKM prescription DRBE (64 Gy(RBE)). D95% and D2% deviations, with respect to the optimization goals in the two RBE systems, increased of 0.5% and 14.2%, respectively, due to the steeper mMKM RBE variation along the beam path. Local recurrences were mainly (63%) reported in areas where CTV coverage was not satisfactory in the original LEM plan and the mMKM analysis showed that OARs constraints were too conservative. Conclusion: No case of local recurrence could be explained by inadequate mMKM target coverage that was not already present in the LEM plan. New constraints have been defined for optic pathways and brainstem to improve target coverage with no expected increase in tissue complications. … (more)
- Is Part Of:
- Radiotherapy and oncology. Volume 141(2019)
- Journal:
- Radiotherapy and oncology
- Issue:
- Volume 141(2019)
- Issue Display:
- Volume 141, Issue 2019 (2019)
- Year:
- 2019
- Volume:
- 141
- Issue:
- 2019
- Issue Sort Value:
- 2019-0141-2019-0000
- Page Start:
- 227
- Page End:
- 233
- Publication Date:
- 2019-12
- Subjects:
- Carbon ion therapy -- Relative biological effectiveness modeling -- Adenoid cystic carcinoma
Oncology -- Periodicals
Radiotherapy -- Periodicals
Tumors -- Periodicals
Medical Oncology -- Periodicals
Neoplasms -- radiotherapy -- Periodicals
Radiotherapy -- Periodicals
Radiothérapie -- Périodiques
Cancérologie -- Périodiques
Tumeurs -- Périodiques
Electronic journals
616.9940642 - Journal URLs:
- http://www.sciencedirect.com/science/journal/01678140 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/01678140 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/01678140 ↗
http://www.estro.org/ ↗
http://www.elsevier.com/journals ↗
http://www.journals.elsevier.com/radiotherapy-and-oncology/ ↗ - DOI:
- 10.1016/j.radonc.2019.08.022 ↗
- Languages:
- English
- ISSNs:
- 0167-8140
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 7240.790000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 12460.xml